Dishman Carbogen Amcis Limited Q1 FY27 Earnings Conference Call Transcript Released
Dishman Carbogen Amcis Limited released its Q1 FY27 earnings call transcript. Revenue for Q1 FY27 was INR 6,776 million, a 4% decrease YoY. EBITDA stood at INR 600 million. The company is planning to raise funds via external commercial borrowing at a 4% interest rate to prepay high-cost debt. For FY27, single-digit revenue growth is projected.
The release of the conference call transcript provides detailed insights into the company's operational performance, strategic initiatives, and financial outlook. The information regarding revenue decline, EBITDA drop, and plans for debt refinancing are material for investors. However, the overall impact is moderate as it is a disclosure of information rather than a new strategic announcement.
The transcript details operational updates and financial performance for Q1 FY27. While there are positive operational developments and plans for debt refinancing, the reported revenue saw a 4% decline YoY due to a postponed order, leading to a significant drop in EBITDA. The financial outlook for the full year is cautiously optimistic.
Dishman Carbogen Amcis Limited has released the transcript of its earnings conference call held on August 17, 2026, to discuss the financial results for the quarter ending June 30, 2026.
The call featured insights from Stephan Fritschi (CEO, Carbogen Amcis), Paolo Armanino (COO, India), Harshil Dalal (Global CFO), and Angela Ameriks (Chief Commercial Officer).
Key operational updates included the hiring of Angela Ameriks as Global Chief Commercial Officer to intensify sales focus, the success of the SPRINT initiative for early-phase projects, and increased interaction between Dishman Carbogen Amcis and Carbogen Amcis for process transfers to India, aiming for lower prices and maintained quality for customers.
The drug substance business has successfully transitioned multiple Phase II projects to late-phase programs, with over 13 now in the portfolio, including ADC-related molecules with high FDA priority. A new commercial product approved by the U.S. FDA has been added to the portfolio.
Paolo Armanino highlighted the successful completion of inspections by the Ministry of Food and Drug Safety (MFDS) of South Korea at the Naroda site, and that both Bavla and Naroda sites hold certifications from major international health authorities. The company also secured two CEPs from EDQM in Europe and two new liquid softgel drug products were approved in Myanmar. A commercial contract was signed with a U.S. company for a tech transfer of a legacy project from Switzerland to the Bavla site, expected to be completed within the financial year. A second major legacy project tech transfer from a Swiss MNC has also been approved and initiated, with three other tech transfer projects from Switzerland to India in advanced discussion.
Financially, for the quarter ending June 30, 2026, income from operations was INR 6,776 million, a 4% decrease from INR 7,080 million in the comparable quarter of the previous year. This decline was attributed to a postponed order worth approximately INR 10 million. EBITDA stood at INR 600 million, down from INR 1,406 million in the previous year's comparable quarter. The CDMO segment posted revenue of INR 5,343 million, while the Marketable Molecules segment showed significant growth with revenue at INR 1,432 million. The company is working on refinancing high-cost debt, with plans to raise funds in foreign currency at the promoter entity level to infuse into the Indian entity, aiming for a 4% interest cost over a 10-year tenor.
For FY27, the company expects single-digit revenue growth and EBITDA margins similar to or slightly higher than the previous year. For FY28-29, substantial double-digit growth is anticipated for both Indian operations and the CDMO business out of Switzerland and France, aiming for over 10% YoY revenue growth and EBITDA margins closer to 25-26%.
What to do with a filing like this
Dishman Carbogen Amcis Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Dishman Carbogen Amcis Limited. Read the original for the full detail.